SUPPORTING INFORMATION Additional Supporting

2 downloads 0 Views 169KB Size Report
(NM_001287593), 590-709, 120 bp; CLIC2 (NM_001289), 444-563, 120 bp; CLIC3. (NM_004669), 246-377, 130 bp; CLIC4 (NM_013943), 364-483, 120 bp; ...

SUPPORTING INFORMATION Additional Supporting Information may be found online in the supporting information tab for this article.

Supplementary Methods The following gene-specific PCR primers of human origin were used in real-time PCR: HER2 (GenBank accession number, NM_002512), 288-408, 121 bp; ClC-1 (NM_000083), 1181-1301, amplicon=121 bp; ClC-2 (NM_004366), 1007-1127, 121 bp; ClC-3 (AF029346), 2111-2239, 129 bp; ClC-4 (NM_001830), 737-871, 135 bp; ClC-5 (NM_001127899), 1211-1339, 129 bp; ClC-6 (NM_001286), 937-1060, 124 bp; ClC-7 (AF224741), 1036-1156, 121 bp; ANO1 (NM_002250), 1475-1595, 121 bp; CLIC1 (NM_001287593), 590-709, 120 bp; CLIC2 (NM_001289), 444-563, 120 bp; CLIC3 (NM_004669), 246-377, 130 bp; CLIC4 (NM_013943), 364-483, 120 bp; CLIC5 (NM_001114086), 580-699, 120 bp; CLIC6 (NM_001317009), 1970-2087, 118 bp; AP2α (NM_003220), 787-906, 120 bp; AP-2β (NM_003221), 1134-1253, 120 bp; AP-2γ (NM_003222), 828-947, 120 bp; EGR2 (NM_000399), 590-711, 122 bp; STAT3 (NM_139276), 1263-1382, 120 bp; Foxp3 (NM_014009), 1253-1372, 120 bp; EBP1 (U87954), 653-772, 120 bp; MBP-1 (M55914), 690-809, 120 bp; HDAC3 (NM_003883, 699-819), 121 bp; HDAC6 (NM_006044, 3517-3637), 121 bp; β-actin (ACTB) (NM_001101, 411-511), 101 bp.

B. ClC-3

A. ANO1

0.06

0.04

0.02



ratio to ACTB

ratio to ACTB

0.06

0.04

0.02

0.00

0.00

D. CLIC1

C. ClC-7

0.3

0.04

0.00



ratio to ACTB

ratio to ACTB

0.06

0.02



0.2

0.1 

0.0

Figure S1. Transfection efficacy of siRNAs in MDA-MB-453 cells. A-D: Real-time PCR assay for ANO1 (A), ClC-3 (B), ClC-7 (C), and CLIC1 (D) in si-cont-, siANO1-, si-ClC-3-, si-ClC-7-, and si-CLIC1-transfected MDA-MB-453 cells (n=4 for each). Expression levels were expressed as a ratio to ACTB.

B

A

1.5

1.0

0.5

relative expression (P-STAT3 / STAT3)

relative expression (P-Akt / Akt)

1.5

0.0

0.5

0.0

D

C

1.5

1.0

0.5

0.0

relative expression (P-STAT3 / STAT3)

1.5

relative expression (P-Akt / Akt)

1.0

1.0

0.5

0.0

Figure S2. Effects of the expression levels of phosphorylated AKT (P-AKT) and phosphorylated STAT3 (P-STAT3) proteins on siRNA-mediated inhibition of ANO1 for 72 hr in MDA-MB-453 cells (A, B) and siRNA-mediated inhibition of ClC-3 for 72 hr in YMB-1 cells (C, D). Immunoblotting was performed as shown in Figure 7. After compensation, the ratio of P-AKT to AKT or P-STAT3 to STAT3 in si-cont was expressed as 1.0 (n=4 for each).

B

A

HER2

HER2

(185 kDa)

185 kDa)

ACTB

ACTB

(43 kDa)

(43 kDa)

Figure S3. Effects of the siRNA-mediated inhibition of Cl- channel/transporter subtypes expression levels of HER2 proteins in YMB-1 cells. A, B: Protein lysates of si-cont-, ANO1-, si-ClC-3-, si-ClC-7-, and si-CLIC1-transfected YMB-1 cells were probed immunoblotting with anti-HER2 (upper panel) and anti-ACTB (lower panel) antibodies the same filter.

on siby on

0.1

0.2

0.1

E. EBP1

F. MBP-1

0.2

0.4

0.1

0.0

ratio to ACTB

0.0

ratio to ACTB

0.0

0.2

0.0

0.10

0.04

0.02

0.00

ratio to ACTB

0.2

D. STAT3

0.06

ratio to ACTB

0.3

C. AP-2γ

0.05

0.00

G. HDAC6 0.03

ratio to ACTB

0.3

ratio to ACTB

B. AP-2β

ratio to ACTB

A. AP-2α

0.02

0.01

0.00

Figure S4. Effects of the treatment with T16-inh-A01 (10 μM) for 48 hr on expression levels of HER2-related transcriptional factor transcripts in YMB-1 cells. A-G: Real-time PCR assay for AP-2α (A), AP-2β (B), AP-2γ (C), STAT3 (D), EBP1 (E), MBP-1 (F), and HDAC6 (G) in vehuicle- and T16-inh-A01-treated YMB-1 cells (n=4 for each). Expression levels were expressed as a ratio to ACTB. Results are expressed as means ± SEM.